We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.
- Authors
Levin, Myron J; Smith, Jeffrey G; Kaufhold, Robin M; Barber, Debra; Hayward, Anthony R; Chan, Christina Y; Chan, Ivan S F; Li, David J J; Wang, William; Keller, Paul M; Shaw, Alan; Silber, Jeffrey L; Schlienger, Katia; Chalikonda, Ira; Vessey, S J R; Caulfield, Michael J
- Abstract
The safety and immunogenecity of a booster dose of live attenuated varicella-zoster virus (VZV) vaccine was evaluated in 196 healthy subjects, >or=60 years old, who had already received a VZV vaccine >5 years before. This repeat booster dose was well tolerated. Cell-mediated immunity (CMI) to VZV was measured by an interferon-gamma (IFN-gamma) enzyme-linked immunosorbent spot-forming cell (ELISPOT) assay and a limiting dilution responder cell frequency (RCF) assay. Prevaccination responses decreased as a function of increasing age but were detectable in all subjects by use of the IFN-gamma ELISPOT assay. In most subjects, VZV-specific CMI was increased at 6 weeks postvaccination. The magnitude of the vaccine-induced IFN-gamma ELISPOT response was inversely related to prevaccination values. Although there was a significant correlation between the IFN-gamma ELISPOT and RCF assays, the ELISPOT assay had greater sensitivity and a wider dynamic range. A live attenuated VZV vaccine is safe and immunogenic in an elderly population, and the vaccine-induced immunity may be monitored by the IFN-gamma ELISPOT assay.
- Publication
The Journal of infectious diseases, 2003, Vol 188, Issue 9, p1336
- ISSN
0022-1899
- Publication type
Journal Article
- DOI
10.1086/379048